The weekly litigation news digest is live. Subscribe now
Methods Of Treating Pulmonary Arterial Hypertension - EP4065119
The patent EP4065119 was granted to Actelion Pharmaceuticals on Sep 4, 2024. The application was originally filed on Nov 27, 2020 under application number EP20820054A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4065119
- Application Number
- EP20820054A
- Filing Date
- Nov 27, 2020
- Status
- Granted And Under Opposition
- Aug 2, 2024
- Publication Date
- Sep 4, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
Initial combination therapy of macitentan, tadalafil, and selexipag for treating pulmonary arterial hypertension (PAH) with a unique dosing regimen. The therapy combines the endothelin receptor antagonist macitentan, phosphodiesterase type 5 inhibitor tadalafil, and prostacyclin receptor agonist selexipag, with macitentan and tadalafil initiated on day 1 and selexipag on day 15 ± 3 days. This regimen achieves significant hemodynamic and functional improvements in newly diagnosed PAH patients, with a notable reduction in pulmonary vascular resistance and improvement in right heart function.
Patent Family
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (21) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents